Efficacy of human lyme disease vaccine formulations in a mouse model

S. R. Telford, F. S. Kantor, Y. Lobet, Stephen W Barthold, A. Spielman, R. A. Flavell, E. Fikrig

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Although immunization with recombinant outer surface protein A (OspA) appears to protect mice against infection by the agent of Lyme disease, all reported experiments have involved formulations that would not be suitable for use in humans or have not used realistic challenges. This study was designed to determine whether vaccines prepared and used in a phase I human trial, including one currently being used for a phase II trial in sites with endemic Borrelia burgdorferi, conferred protection in the C3H/HeJ mouse model. The challenge was ticks collected from a major site of the trial. None of the vaccinated mice became infected or developed disease, whereas 60% of unvaccinated mice became infected. Spirochetes were destroyed within the guts of virtually all recovered challenge ticks. These preparations of recombinant OspA effectively induced immunity to protect mice from Lyme disease when bitten by ticks collected from a field trial site.

Original languageEnglish (US)
Pages (from-to)1368-1370
Number of pages3
JournalJournal of Infectious Diseases
Volume171
Issue number5
StatePublished - 1995
Externally publishedYes

Fingerprint

Lyme Disease Vaccines
Ticks
Lyme Disease
Spirochaetales
Borrelia burgdorferi
Inbred C3H Mouse
Immunity
Immunization
Vaccines
Infection

ASJC Scopus subject areas

  • Immunology
  • Public Health, Environmental and Occupational Health

Cite this

Telford, S. R., Kantor, F. S., Lobet, Y., Barthold, S. W., Spielman, A., Flavell, R. A., & Fikrig, E. (1995). Efficacy of human lyme disease vaccine formulations in a mouse model. Journal of Infectious Diseases, 171(5), 1368-1370.

Efficacy of human lyme disease vaccine formulations in a mouse model. / Telford, S. R.; Kantor, F. S.; Lobet, Y.; Barthold, Stephen W; Spielman, A.; Flavell, R. A.; Fikrig, E.

In: Journal of Infectious Diseases, Vol. 171, No. 5, 1995, p. 1368-1370.

Research output: Contribution to journalArticle

Telford, SR, Kantor, FS, Lobet, Y, Barthold, SW, Spielman, A, Flavell, RA & Fikrig, E 1995, 'Efficacy of human lyme disease vaccine formulations in a mouse model', Journal of Infectious Diseases, vol. 171, no. 5, pp. 1368-1370.
Telford SR, Kantor FS, Lobet Y, Barthold SW, Spielman A, Flavell RA et al. Efficacy of human lyme disease vaccine formulations in a mouse model. Journal of Infectious Diseases. 1995;171(5):1368-1370.
Telford, S. R. ; Kantor, F. S. ; Lobet, Y. ; Barthold, Stephen W ; Spielman, A. ; Flavell, R. A. ; Fikrig, E. / Efficacy of human lyme disease vaccine formulations in a mouse model. In: Journal of Infectious Diseases. 1995 ; Vol. 171, No. 5. pp. 1368-1370.
@article{96cc8269515844aca7f99cfafd2e477c,
title = "Efficacy of human lyme disease vaccine formulations in a mouse model",
abstract = "Although immunization with recombinant outer surface protein A (OspA) appears to protect mice against infection by the agent of Lyme disease, all reported experiments have involved formulations that would not be suitable for use in humans or have not used realistic challenges. This study was designed to determine whether vaccines prepared and used in a phase I human trial, including one currently being used for a phase II trial in sites with endemic Borrelia burgdorferi, conferred protection in the C3H/HeJ mouse model. The challenge was ticks collected from a major site of the trial. None of the vaccinated mice became infected or developed disease, whereas 60{\%} of unvaccinated mice became infected. Spirochetes were destroyed within the guts of virtually all recovered challenge ticks. These preparations of recombinant OspA effectively induced immunity to protect mice from Lyme disease when bitten by ticks collected from a field trial site.",
author = "Telford, {S. R.} and Kantor, {F. S.} and Y. Lobet and Barthold, {Stephen W} and A. Spielman and Flavell, {R. A.} and E. Fikrig",
year = "1995",
language = "English (US)",
volume = "171",
pages = "1368--1370",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Efficacy of human lyme disease vaccine formulations in a mouse model

AU - Telford, S. R.

AU - Kantor, F. S.

AU - Lobet, Y.

AU - Barthold, Stephen W

AU - Spielman, A.

AU - Flavell, R. A.

AU - Fikrig, E.

PY - 1995

Y1 - 1995

N2 - Although immunization with recombinant outer surface protein A (OspA) appears to protect mice against infection by the agent of Lyme disease, all reported experiments have involved formulations that would not be suitable for use in humans or have not used realistic challenges. This study was designed to determine whether vaccines prepared and used in a phase I human trial, including one currently being used for a phase II trial in sites with endemic Borrelia burgdorferi, conferred protection in the C3H/HeJ mouse model. The challenge was ticks collected from a major site of the trial. None of the vaccinated mice became infected or developed disease, whereas 60% of unvaccinated mice became infected. Spirochetes were destroyed within the guts of virtually all recovered challenge ticks. These preparations of recombinant OspA effectively induced immunity to protect mice from Lyme disease when bitten by ticks collected from a field trial site.

AB - Although immunization with recombinant outer surface protein A (OspA) appears to protect mice against infection by the agent of Lyme disease, all reported experiments have involved formulations that would not be suitable for use in humans or have not used realistic challenges. This study was designed to determine whether vaccines prepared and used in a phase I human trial, including one currently being used for a phase II trial in sites with endemic Borrelia burgdorferi, conferred protection in the C3H/HeJ mouse model. The challenge was ticks collected from a major site of the trial. None of the vaccinated mice became infected or developed disease, whereas 60% of unvaccinated mice became infected. Spirochetes were destroyed within the guts of virtually all recovered challenge ticks. These preparations of recombinant OspA effectively induced immunity to protect mice from Lyme disease when bitten by ticks collected from a field trial site.

UR - http://www.scopus.com/inward/record.url?scp=0028957206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028957206&partnerID=8YFLogxK

M3 - Article

C2 - 7751719

AN - SCOPUS:0028957206

VL - 171

SP - 1368

EP - 1370

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 5

ER -